SMARCA2 and neoplasm: Compared to SMARCA2-positive expression, SMARCA2-negative expression was significantly associated with male sex, a larger tumor size, higher T stage, lymphatic metastasis, higher pathologic stage, pleural invasion, vascular invasion, necrosis, poor differentiation, higher proliferation index, P53 aberrant expression, high PD-L1 expression, and SOX-2-negative expression, and the proportion of SMARCA2-negative expression was higher in the middle lobe lesions than in the other lung lobes (P < 0.05).